Virtual Rehabilitation in HCT
Chronic GVHD (cGVHD) is a major cause of illness in patients who undergo hematopoietic transplantation (HCT). GVHD can affect any organ in the body, can require several years of treatment, and can impact the quality of life (QoL). Physical activity and exercise have been shown to enhance fitness and improve QoL in chro
| Condition(s) | Hematopoietic Cell Transplant |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Chronic GVHD (cGVHD) is a major cause of illness in patients who undergo hematopoietic transplantation (HCT). GVHD can affect any organ in the body, can require several years of treatment, and can impact the quality of life (QoL). Physical activity and exercise have been shown to enhance fitness and improve QoL in chronic illnesses including GVHD, however, patients often have barriers to attending sessions including distance, risk of infection, and physical therapists' lack of experience with pediatric patients. The team's goal is to assess whether a virtual rehabilitation program in children post-HCT (including children with chronic GVHD) is feasible and whether its implementation will improve physical functioning and QoL. Patients between the ages of 8 and 23 years who are at least one h |
| Who can participate | Inclusion Criteria: * Recipients between the ages of 8 and 23 years ≥100 days post allogeneic HCT. * Patients 8-14 years old should have a caregiver willing to assist with the implementation of the exercises during the session * Patients should have access to devices and a reliable internet connection. * Patients should be cleared for exercise by their physician * Patients are eligible to participate regardless of underlying diagnosis, preparative regimen, or graft source. Exclusion Criteria: * Any physical impediment to exercise as evaluated by the treating physician. * Non-English-speaking patients (due to a lack of available interpreters through the telemedicine platform). |
| Ages | 8 Years to 23 Years |
| Sex | All |
| Lead sponsor | Emory University |
| Locations | Atlanta, Georgia, United States |
| Start date | 2023-07-31 |
| NCT ID | NCT05943964 |
| Official listing | https://clinicaltrials.gov/study/NCT05943964 |